• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Contemporary clinical trials >Estimating per patient funding for cancer clinical trials: an Ontario based survey.
【24h】

Estimating per patient funding for cancer clinical trials: an Ontario based survey.

机译：估算每位患者用于癌症临床试验的资金：基于安大略省的调查。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The financial implications of conducting clinical trials in oncology have not been well researched from a perspective that would facilitate the negotiation of appropriate reimbursement. A better understanding of the resources required to conduct clinical trials is central to this process. Summaries of two hypothetical clinical trials were circulated to the clinical trials departments of the nine regional cancer centres of Cancer Care Ontario (CCO), in the Province of Ontario, Canada. The centres were asked to produce itemized budgets with per patient charges detailed for each trial. Additionally, each trial was to be separately considered as if sponsored by a federally funded cooperative group, and then as if sponsored by industry. Six of the centres reported experience generating clinical trial budgets. Specific charges by the local Institutional Review or Research Ethics Boards (REB) were not included. The total of all per patient charges for the first trial ranged from 1352 dollars to 3082 dollars when considered as a cooperative group trial, and from 1700 dollars to 7217 dollars when considered as an industry sponsored trial. Similar charges for the second trial ranged from 2251 dollars to 5826 dollars and from 2251 dollars to 11,304 dollars respectively. Despite the similarities of the regional cancer centres across the province of Ontario, there were surprisingly large differences in the submitted budgets. No centre consistently produced the highest or lowest estimates. The majority of the differences appeared to be based on the range in estimates for professional support (nurse and physician), and the required radiology investigations. For centres that negotiate specific per patient funding amounts with industry, this data would suggest a need to better understand the budgeting process and its link to appropriate resource identification to ensure appropriate funding is obtained. These issues are likely not unique to oncology.
机译：从有利于谈判适当报销的角度，尚未对进行肿瘤临床试验的财务影响进行深入研究。更好地理解进行临床试验所需的资源是此过程的核心。两项假设的临床试验的摘要已分发给加拿大安大略省安大略省癌症护理中心（CCO）的9个地区癌症中心的临床试验部门。要求各中心制定逐项预算，详细列出每项试验的每位患者费用。此外，每个试验都应单独考虑，好像是由联邦资助的合作组织赞助，然后好像是行业赞助。六个中心报告了产生临床试验预算的经验。不包括地方机构审查或研究道德委员会（REB）的特定费用。首次试验的每位患者全部费用的合计范围为从1352美元到3082美元，而作为合作团体试验，则从1700美元到7217美元。第二次审判的类似费用分别为2251美元至5826美元和2251美元至11304美元。尽管整个安大略省的地区癌症中心都相似，但提交的预算中却出乎意料地存在巨大差异。没有哪个中心能够始终如一地得出最高或最低估计值。差异的大部分似乎是基于专业支持（护士和医师）的估计范围以及所需的放射学调查得出的。对于与行业协商每位患者特定资助金额的中心，此数据表明需要更好地了解预算流程及其与适当资源标识的联系，以确保获得适当的资金。这些问题可能不是肿瘤学独有的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号